



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **Agrawal**
Serial No.: **09/770,602**
Filed: **January 26, 2001**
Entitled: **MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES**
Examiner: **Zara, Jane J.**
Group Art Unit: **1635**
Attorney Docket No.: **HYB-003US1 (1006/004)**

Assistant Commissioner for Patents
P. O. Box 1450
Washington, DC 20231-1450

POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST, REVOCATION OF PRIOR POWERS, CHANGE OF CORRESPONDENCE ADDRESS, and CERTIFICATE UNDER 37 C.F.R. 3.73(b)

Sir:

The undersigned Assignee of the above-identified United States patent application hereby revokes all powers of attorney previously created and appoints the following attorneys with full power of substitution and revocation to prosecute the application and to transact all business in the Patent and Trademark Office connected therewith:

Wayne A. Keown, Ph.D. **Reg. No. 33,923**
Joseph C. Zuccheri **Reg. No. 55,762**

All future correspondence should be sent to:

Wayne A. Keown, Ph.D.
Keown & Associates
500 West Cummings Park
Suite 1200
Woburn, MA 01801
Telephone: 781-938-1805
Faxscimile: 781-938-4777

**CERTIFICATE UNDER 37 C.F.R. 3.73(b)**

Hybridon, Inc., a corporation existing under the laws of the State of Delaware, certifies that it is the Assignee of the entire right, title and interest in the patent identified above by virtue of an Assignment from the inventor(s) of the patent application recorded in the United States Patent and Trademark Office on May 6, 2002 at Reel 012872, Frame 0895.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above, and, to the best of the undersigned's knowledge and belief, title is in the Assignee identified above.

The undersigned whose title is supplied below is empowered to act on behalf of the Assignee.

The undersigned further declares that all statements made herein are of its own knowledge and are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the patent.

Respectfully submitted,

By: R. Andersen
Title: EFO

Signature: R.G. ANDERSEN
Date: 12 APRIL 2004